{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:40:24Z","timestamp":1791204024214,"version":"4.2.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clinthera.2016.08.008","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T08:37:08Z","timestamp":1474619828000},"page":"2248-2264.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"38","author":[{"given":"Tim","family":"Heise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeraj","family":"Macha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren S.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Woerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uli C.","family":"Broedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.08.008_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.08.008_bib2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"H\u00e4ring","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.08.008_bib3","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial","volume":"36","author":"H\u00e4ring","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.08.008_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.08.008_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14740330903499240","article-title":"Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds","volume":"9","author":"Sarafidis","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2016.08.008_bib7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/ajcn\/80.5.1379","volume":"80","author":"Muller","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clinthera.2016.08.008_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinthera.2014.12.018","article-title":"Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study","volume":"37","author":"Heise","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.08.008_bib9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","volume":"166","author":"Barzilay","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2016.08.008_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.08.008_bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jash.2013.05.004","article-title":"Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium\u2014a meta-analysis","volume":"7","author":"Mukete","year":"2013","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.clinthera.2016.08.008_bib12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/0002-8703(88)90816-2","article-title":"The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics","volume":"115","author":"Houston","year":"1988","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2016.08.008_bib13","first-page":"581","article-title":"Diuretic resistance: physiology and therapeutics","volume":"19","author":"Ellison","year":"1999","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of torasemide","volume":"34","author":"Knauf","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2016.08.008_bib15","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Inter Suppl"},{"key":"10.1016\/j.clinthera.2016.08.008_bib16","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2016.08.008_bib17","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.08.008_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.08.008_bib19","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.08.008_bib21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/ki.1995.238","article-title":"Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy","volume":"47","author":"Hansen","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2016.08.008_bib22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2016.08.008_bib23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1172\/JCI113120","article-title":"Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration","volume":"80","author":"Ortola","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2016.08.008_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstrale","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.clinthera.2016.08.008_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-199549010-00009","article-title":"Torasemide. An update of its pharmacological properties and therapeutic efficacy","volume":"49","author":"Dunn","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.08.008_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs0670195","article-title":"Factors affecting potassium balance during frusemide administration","volume":"67","author":"Wilcox","year":"1984","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.clinthera.2016.08.008_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2011.09.009","article-title":"Metabolic complications associated with use of diuretics","volume":"31","author":"Palmer","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib30","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm. Drug Dispos"},{"key":"10.1016\/j.clinthera.2016.08.008_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","article-title":"Thiazide and loop diuretics","volume":"13","author":"Sica","year":"2011","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.clinthera.2016.08.008_bib33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2014.11.016","article-title":"Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial","volume":"65","author":"Goicoechea","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2016.08.008_bib35","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1681\/ASN.2014070660","article-title":"Uric acid and cardiovascular events: a mendelian randomization study","volume":"26","author":"Kleber","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2016.08.008_bib36","doi-asserted-by":"crossref","first-page":"f4262","DOI":"10.1136\/bmj.f4262","article-title":"Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts","volume":"347","author":"Palmer","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2016.08.008_bib37","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance following sodium-glucose co-transporter-2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816306555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816306555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T19:20:41Z","timestamp":1568402441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816306555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0149291816306555"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}